IN2014MN02213A - - Google Patents
Info
- Publication number
- IN2014MN02213A IN2014MN02213A IN2213MUN2014A IN2014MN02213A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A IN 2213MUN2014 A IN2213MUN2014 A IN 2213MUN2014A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A
- Authority
- IN
- India
- Prior art keywords
- formulations
- incision
- infiltration
- api
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Botany (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645066P | 2012-05-10 | 2012-05-10 | |
US201261649400P | 2012-05-21 | 2012-05-21 | |
US201361781595P | 2013-03-14 | 2013-03-14 | |
US201361781625P | 2013-03-14 | 2013-03-14 | |
PCT/IL2013/050404 WO2013168167A1 (en) | 2012-05-10 | 2013-05-09 | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02213A true IN2014MN02213A (sv) | 2015-07-10 |
Family
ID=49550270
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2213MUN2014 IN2014MN02213A (sv) | 2012-05-10 | 2013-05-09 | |
IN2214MUN2014 IN2014MN02214A (sv) | 2012-05-10 | 2013-05-09 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2214MUN2014 IN2014MN02214A (sv) | 2012-05-10 | 2013-05-09 |
Country Status (9)
Country | Link |
---|---|
US (3) | US9849088B2 (sv) |
EP (2) | EP2846772A4 (sv) |
JP (4) | JP2015516411A (sv) |
CN (2) | CN104427976B (sv) |
AU (2) | AU2013257546B2 (sv) |
CA (2) | CA2871820C (sv) |
IN (2) | IN2014MN02213A (sv) |
RU (2) | RU2678433C2 (sv) |
WO (2) | WO2013168167A1 (sv) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013168167A1 (en) * | 2012-05-10 | 2013-11-14 | Painreform Ltd. | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
WO2017009861A1 (en) * | 2015-07-13 | 2017-01-19 | Neon Laboratories Limited | Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof |
CA3078555A1 (en) | 2017-10-06 | 2019-04-11 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
WO2019226599A1 (en) * | 2018-05-22 | 2019-11-28 | Alkalidx, Inc. | Diagnostics and treatments of anesthetic insensitive subjects |
CN109316602A (zh) * | 2018-11-13 | 2019-02-12 | 西安力邦医药科技有限责任公司 | 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用 |
JP7378929B2 (ja) * | 2018-12-27 | 2023-11-14 | 花王株式会社 | リポソームの製造方法 |
CN111388418B (zh) * | 2018-12-31 | 2022-09-06 | 北京泰德制药股份有限公司 | 一种含有罗哌卡因或其药用盐的药物组合物 |
EP3991722A4 (en) * | 2019-06-28 | 2022-10-05 | Jiangsu Hengrui Medicine Co., Ltd. | LIPID COMPOSITION WITH DELAYED RELEASE AND THEIR PROCESS OF PRODUCTION |
EP4091612A4 (en) * | 2020-01-14 | 2024-01-24 | Shanghai Inst Materia Medica Cas | PHARMACEUTICAL COMPOSITION OF LONG-ACTING ROPIVACAINE, PREPARATION METHOD AND USE THEREOF |
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
CN115463084B (zh) * | 2021-06-10 | 2024-05-28 | 北京泰德制药股份有限公司 | 一种长效镇痛用复方油溶液制剂及其制备方法 |
CN117999070A (zh) * | 2021-09-15 | 2024-05-07 | 美国奥科视光有限公司 | 用于治疗干燥皮肤的软膏 |
WO2024050176A1 (en) * | 2022-08-27 | 2024-03-07 | Rubin Darren Alexander | Injectable methods to treat deficiencies in glutathione metabolism and homocystinuria |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4252793A (en) | 1979-06-18 | 1981-02-24 | American Lecithin Company | Injectable lecithin preparation |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
JPH0753661B2 (ja) | 1984-03-08 | 1995-06-07 | フアレス フアーマスーチカル リサーチ エヌブイ | プロ―リポソーム組成物及びリポソームの水性分散物を作る方法 |
US5173219A (en) | 1986-02-12 | 1992-12-22 | Research Development Foundation | Uniform spherical multilamellar liposomes of defined and adjustable size distribution |
US5723147A (en) | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
NZ223660A (en) | 1987-03-05 | 1990-11-27 | Liposome Co Inc | Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity |
CH681427A5 (sv) | 1987-07-01 | 1993-03-31 | Zambon Spa | |
US5807572A (en) | 1988-02-18 | 1998-09-15 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
US5576017A (en) | 1988-05-30 | 1996-11-19 | Depotech Corporation | Heterovesicular liposomes |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
EP0643620B1 (en) * | 1991-10-04 | 1999-07-21 | Gs Development Ab | Particles, method of preparing said particles and uses thereof |
SE9200952D0 (sv) | 1992-03-27 | 1992-03-27 | Kabi Pharmacia Ab | Pharmaceutical carrier system containing defined lipids |
US5922340A (en) | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
ATE195652T1 (de) | 1992-12-02 | 2000-09-15 | Alkermes Inc | Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung |
US5759573A (en) | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
US5455044A (en) | 1993-05-14 | 1995-10-03 | Depotech Corporation | Method for treating neurological disorders |
SE9302218D0 (sv) * | 1993-06-28 | 1993-06-28 | Ab Astra | New use |
CA2166465C (en) * | 1993-07-08 | 2003-10-14 | Laura M. Edgerly-Pflug | Method of controlling the size of liposomes |
US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
ATE288270T1 (de) | 1993-11-19 | 2005-02-15 | Janssen Pharmaceutica Nv | Mikroverkapselte 1,2-benzazole |
US5635206A (en) * | 1994-01-20 | 1997-06-03 | Hoffmann-La Roche Inc. | Process for liposomes or proliposomes |
CA2153553A1 (en) | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Stable lipid emulsion |
US5993850A (en) | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
HU223475B1 (hu) * | 1994-10-24 | 2004-07-28 | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. | Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US5981592A (en) | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
US6160018A (en) | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
CA2230448A1 (en) | 1995-08-28 | 1997-03-06 | Showa Yakuhin Kako Co., Ltd. | Composition for local anesthesia |
ATE183092T1 (de) * | 1995-10-28 | 1999-08-15 | Braun Melsungen Ag | Lokalanästhetika und/oder zentralanalgetika enthaltende pharmazeutische zusammensetzungen |
US5744337A (en) * | 1995-12-26 | 1998-04-28 | The United States Of America As Represented By The Secretary Of The Navy | Internal gelation method for forming multilayer microspheres and product thereof |
FR2753626B1 (fr) | 1996-09-20 | 1998-11-06 | Centre International De Rech Dermatologiques Galderma Cird Galderma | Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant |
US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
AU7389098A (en) * | 1997-05-16 | 1998-12-08 | Brigham And Women's Hospital | Local anesthetic formulations |
GB2326337A (en) | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
US6306432B1 (en) | 1997-09-08 | 2001-10-23 | Chiron Corporation | High and low load formulations of IGF-I in multivesicular liposomes |
US6106858A (en) | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
JP4467789B2 (ja) * | 1997-09-18 | 2010-05-26 | パシラ ファーマシューティカルズ インコーポレーテッド | 持続放出性リポソーム麻酔組成物 |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
EP0996461B1 (en) | 1997-10-31 | 2005-01-12 | Walter Reed Army Institute of Research | Use of a complement activation inhibitor in the manufacture of a medicament for inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
CA2309548A1 (en) | 1997-11-14 | 1999-05-27 | Skyepharma Inc. | Production of multivesicular liposomes |
BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
US6277413B1 (en) | 1998-07-17 | 2001-08-21 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
ATE262916T1 (de) * | 1998-08-18 | 2004-04-15 | Panacea Biotec Ltd | Zusammensetzung enthalten cyclsoporin in einem hydrophilen träger |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
GB9907715D0 (en) * | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
EP1189597A4 (en) | 1999-06-04 | 2008-06-18 | Pacira Pharmaceuticals Inc | COMPOSITIONS USING AN OIL CORE FOR DELAYED RELEASE HYDROPHOLE MEDICAMENTS |
KR100343125B1 (ko) | 1999-09-14 | 2002-07-05 | 임정옥 | 도포용 리포좀형 혼합국소마취제 및 그 제조방법 |
EP1138313A1 (de) * | 2000-03-28 | 2001-10-04 | Primacare S.A. | Pro-liposomen |
US6761901B1 (en) | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
IL139177A0 (en) | 2000-10-20 | 2001-11-25 | S C Republic Dev S R L | Sustained release drug delivery system |
AU2002322024B2 (en) | 2001-05-31 | 2008-05-08 | Pacira Pharmaceuticals, Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
US20030099674A1 (en) | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
WO2003047595A1 (en) | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
AU2003226285B2 (en) | 2002-04-10 | 2008-01-03 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
US7229630B2 (en) | 2002-06-20 | 2007-06-12 | Novalar Pharmaceuticals, Inc. | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
US20030236306A1 (en) | 2002-06-20 | 2003-12-25 | Chen Andrew X. | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
AU2003266159A1 (en) * | 2002-09-16 | 2004-04-30 | Zicam, Llc. | System and method for delivering a composition to the nasal membrane |
CA2501239A1 (en) | 2002-10-07 | 2004-04-22 | Encore Pharmaceuticals, Inc. | R-nsaid esters and their use |
US20050026877A1 (en) | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20050020546A1 (en) | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20060189586A1 (en) | 2003-06-11 | 2006-08-24 | Cleland Jeffrey L | Pharmaceutical compositions comprising active vitamin D compounds |
US20050049209A1 (en) | 2003-08-06 | 2005-03-03 | Chen Andrew Xian | Pharmaceutical compositions for delivering macrolides |
US20050118206A1 (en) | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US7968122B2 (en) | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
US20050186230A1 (en) | 2004-01-23 | 2005-08-25 | Sd Pharmaceuticals, Inc. | Elemene compositions containing liquid oil |
WO2005082382A1 (en) | 2004-02-23 | 2005-09-09 | Attenuon Llc | Formulations of thiomolybdate or thiotungstate compounds and uses thereof |
ES2309766T3 (es) | 2004-06-04 | 2008-12-16 | Camurus Ab | Formulaciones liquidas de liberacion lenta. |
JP2008502690A (ja) * | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン, | リン脂質組成物ならびにその調製方法および使用方法 |
US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
EP1778217A4 (en) | 2004-07-28 | 2008-10-08 | Sd Pharmaceuticals Inc | STABLE INJECTABLE COMPOSITION OF ALPHA-TOCOPHERYLSUCCINATE; ANALOGUE AND SALTS FROM IT " |
US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
KR20080039400A (ko) | 2005-07-07 | 2008-05-07 | 파남 컴퍼니스 인크. | 고수용성 약물의 서방성 약학 조성물 |
US20070078434A1 (en) * | 2005-09-30 | 2007-04-05 | Vyteris, Inc. | Indications For Local Transport of Anaesthetic Agents By Electrotransport Devices |
CA2631755A1 (en) | 2005-12-02 | 2007-06-07 | Adventrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate |
CN100518738C (zh) | 2006-01-06 | 2009-07-29 | 中国药科大学 | 一种含喜树碱类药物的自组装前体脂质体及其制备方法 |
CN100563715C (zh) | 2006-01-06 | 2009-12-02 | 中国药科大学 | 一种紫杉醇自组装前体脂质体及其制备方法 |
CN100486569C (zh) | 2006-01-06 | 2009-05-13 | 中国药科大学 | 一种多烯紫杉醇自组装前体脂质体及其制备方法 |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
WO2008127456A2 (en) * | 2006-12-07 | 2008-10-23 | Lyotropic Therapeutics, Inc. | Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use |
EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
US20100041704A1 (en) * | 2007-01-12 | 2010-02-18 | Aberg A K Gunnar | Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus |
ATE476176T1 (de) | 2007-03-02 | 2010-08-15 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
CA2681302C (en) * | 2007-03-19 | 2013-07-23 | Dhiraj Khattar | Proliposomal and liposomal compositions of poorly water-soluble compounds |
BRPI0704542B8 (pt) | 2007-05-15 | 2021-05-25 | Univ Estadual Campinas Unicamp | composição farmacêutica, processo de obtenção da composição farmacêutica, uso de uma quantidade farmaceuticamente eficaz de anestésico e agente gelificante, produto e método de tratamento |
RU2429242C2 (ru) * | 2007-05-30 | 2011-09-20 | Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) | Применение тетранитрозильного комплекса железа с тиофенолом в качестве противоопухолевого лекарственного средства |
HUP0700426A2 (en) | 2007-06-19 | 2010-03-29 | Invencio 21 Gyogyhatasu Keszit | Liposomal compound |
EP2178893A4 (en) | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | ORAL FORMULATIONS FOR PICOPLATIN |
FR2924024B1 (fr) | 2007-11-27 | 2012-08-17 | Centre Nat Rech Scient | Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse |
CN101485629B (zh) | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
CN102202654B (zh) | 2008-09-04 | 2014-07-30 | 法纳姆公司 | 可咀嚼的缓释制剂 |
US9248098B2 (en) | 2008-10-10 | 2016-02-02 | Dara Biosciences, Inc. | Treating or preventing pain using spicamycin derivatives |
WO2010138918A1 (en) | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
WO2011031462A2 (en) | 2009-08-25 | 2011-03-17 | Latitude Pharmaceuticals Incorporated | Compositions for delivery of insoluble agents |
CN102933200B (zh) | 2009-12-18 | 2015-11-25 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
EP2336286A1 (en) * | 2009-12-18 | 2011-06-22 | The Procter & Gamble Company | Composition comprising microcapsules |
US8313766B2 (en) | 2010-02-05 | 2012-11-20 | Andrew Chen | Oral antidepressant formulation with reduced excipient load |
US20140066481A1 (en) | 2010-04-01 | 2014-03-06 | Pharmanest Ab | Water-Free Pharmaceutical Compositions Suitable for Local Anaesthetics |
US20110250264A1 (en) | 2010-04-09 | 2011-10-13 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
WO2011153513A2 (en) | 2010-06-03 | 2011-12-08 | Latitude Pharma | Nanoemulsion composition containing vitamin k |
EP2588081A4 (en) | 2010-06-29 | 2014-12-10 | Verastem Inc | ORAL FORMULATION OF CHINESE INHIBITORS |
CN103052382B (zh) | 2010-07-14 | 2014-10-22 | 千寿制药株式会社 | α-酮酰胺衍生物的固体分散体 |
AU2010359346B2 (en) | 2010-08-20 | 2015-01-29 | Dr. Reddy's Laboratories Sa | Phospholipid depot |
WO2012037311A1 (en) | 2010-09-17 | 2012-03-22 | Maine Natural Health, Inc. | Compositions containing omega-3 oil and uses thereof |
WO2012054447A2 (en) | 2010-10-22 | 2012-04-26 | Dr. Reddy's Laboratories, Inc. | Use of storage stable viscous phospholipid depot to treat wounds |
JP6194248B2 (ja) | 2010-10-28 | 2017-09-06 | パシラ ファーマシューティカルズ インコーポレーテッド | 非ステロイド性抗炎症薬の徐放性処方物 |
WO2012170796A1 (en) | 2011-06-09 | 2012-12-13 | Amylin Pharmaceuticals, Inc. | Gel compositions |
WO2013168167A1 (en) * | 2012-05-10 | 2013-11-14 | Painreform Ltd. | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
-
2013
- 2013-05-09 WO PCT/IL2013/050404 patent/WO2013168167A1/en active Application Filing
- 2013-05-09 CA CA2871820A patent/CA2871820C/en active Active
- 2013-05-09 IN IN2213MUN2014 patent/IN2014MN02213A/en unknown
- 2013-05-09 CN CN201380036669.XA patent/CN104427976B/zh active Active
- 2013-05-09 AU AU2013257546A patent/AU2013257546B2/en active Active
- 2013-05-09 CA CA2871821A patent/CA2871821C/en active Active
- 2013-05-09 RU RU2014144501A patent/RU2678433C2/ru active
- 2013-05-09 JP JP2015510942A patent/JP2015516411A/ja active Pending
- 2013-05-09 US US14/399,884 patent/US9849088B2/en active Active
- 2013-05-09 US US14/399,815 patent/US9668974B2/en active Active
- 2013-05-09 CN CN201380036700.XA patent/CN104427977B/zh active Active
- 2013-05-09 WO PCT/IL2013/050410 patent/WO2013168172A1/en active Application Filing
- 2013-05-09 AU AU2013257608A patent/AU2013257608B2/en active Active
- 2013-05-09 IN IN2214MUN2014 patent/IN2014MN02214A/en unknown
- 2013-05-09 JP JP2015510944A patent/JP2015516412A/ja active Pending
- 2013-05-09 RU RU2014144500A patent/RU2664700C2/ru active
- 2013-05-09 EP EP13787409.5A patent/EP2846772A4/en active Pending
- 2013-05-09 EP EP13787930.0A patent/EP2846773A4/en active Pending
-
2017
- 2017-05-02 US US15/584,391 patent/US10206876B2/en active Active
- 2017-10-03 JP JP2017193516A patent/JP6574228B2/ja active Active
- 2017-10-04 JP JP2017194260A patent/JP6577548B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02213A (sv) | ||
AU2018256640A1 (en) | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | |
MX2021006035A (es) | Formulaciones cannabinoides estables. | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
EP4285928A3 (en) | Anti-pdl1 antibody formulations | |
MX2019003693A (es) | Formulaciones de insulina de accion prolongada. | |
MX2014011181A (es) | Microemulsiones basadas en ciclodextrina y usos dermatologicos de las mismas. | |
MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
MX369121B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
MD20150050A2 (ro) | Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare | |
MX2021010359A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
EP4360621A3 (en) | Formulations of bendamustine | |
IN2014DN00277A (sv) | ||
IN2014MN01470A (sv) | ||
MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
DOP2017000307A (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma. | |
PH12015502556A1 (en) | Modified release formulation | |
MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
EP2981258B8 (en) | Pharmaceutical formulations for subcutaneous administration of furosemide | |
JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
WO2013100869A3 (en) | Lipid-based nanocarrier systems for using cancer treatment | |
BR112017019364A2 (pt) | dispersões sólidas | |
IN2014DN09246A (sv) | ||
GB201204632D0 (en) | Delivery system | |
EP2668952A3 (en) | Aqueous formulations of bisphosphonates, vitamin D and benzyl alcohol suitable for subcutaneous or intramuscular use |